Kerry joined Alström Syndrome UK (ASUK) in 2003 when it was first suggested that her son might have the condition. His diagnosis was later confirmed through genetic testing. Kerry has held various roles during her time at ASUK and was appointed Chief Executive in November 2021.

Kerry brings extensive experience in patient and public involvement and has contributed to numerous UK, EU, and global projects focused on patient input into clinical trial design and drug development. She serves as a patient representative on the England Rare Diseases Framework Delivery Group and is a co-applicant on several NIHR-funded research studies.

Kerry thoroughly enjoys her role at ASUK, particularly the direct contact with children, young people, adults, families, and carers affected by Alström Syndrome and other rare or genetic conditions. She works alongside a dedicated team at ASUK, and together they remain deeply committed to ensuring all work is led by people with lived experience.